• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Video

Why Short-Sellers Ackman, Chanos and Kass Are Flirting With Danger

The natural bias of the market is upward, so short-sellers are going against consensus at their own peril when they bet against a stock.
By GREGG GREENBERG
Sep 25, 2015 | 03:06 PM EDT
Stocks quotes in this article: HLF, BRK-A

The natural bias of the market is upward, so short-sellers are going against consensus at their own peril when they bet against a stock, said Richard Teitelbaum, author of The Most Dangerous Trade. 'You are also open to short squeezes where long investors gang up, buy up stock and run it up and you are going to be forced to cover over a period of time and that can cost you a lot of money,' said Teitelbaum. For example, Teitelbaum profiled Bill Ackman of Pershing Square Capital Management in his book. Ackman made a splash in late 2012 when he announced his Herbalife short, sending the stock plummeting to what seemed like an easy victory and substantial profit. Unfortunately for Ackman, Herbalife fought back with vigor. Other hedge fund managers like Carl Icahn and Dan Loeb jumped into the fray and forced a short squeeze. Not one to back down, the billionaire hedge fund manager vowed to 'take it to the end of the earth' and that battle continues to rage on. 'Herbalife was very successful in attracting people who disagreed with Bill Ackman,' said Teitelbaum. Teitelbaum refers to Jim Chanos, president and founder of Kynikos Associates, as the 'dean' of short-selling. Chanos sold short shares of energy trading giant Enron throughout 2001, increasing his short position as more information about its sketchy dealings surfaced. Kynikos pocketed a huge sum from its Enron short and Chanos became well known for his early detection of Enron's problems. 'He identifies different short situations that he can profit from and he is very good at executing,' said Teitelbaum.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

TAGS: Investing | Video | Consumer Staples | Financial Services | Hedge Funds | Retail | Opinion | Short-selling | China | Stocks | Executive Interview

More from Video

Amid the Selling, Here's the Big Question Now

James "Rev Shark" DePorre
Feb 25, 2021 4:43 PM EST

How quickly do we find support, is what we'll want to know now, as the correction is occurring while economic optimism builds.

One Tweet Pulls the Rug Out From Under the Indexes

James "Rev Shark" DePorre
Oct 6, 2020 4:44 PM EDT

Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.

A Technical Look at the New Dow Jones Industrial Average

Bruce Kamich
Aug 25, 2020 1:11 PM EDT

Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.

Conagra Brands Looks Tastier After Its Upgrade to Buy

Bruce Kamich
Dec 30, 2019 12:39 PM EST

CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.

Biogen Bulls Get a Lift From Quant Upgrade and Strengthening Charts

Bruce Kamich
Oct 30, 2019 1:13 PM EDT

Breaking down an approach to the long side of this biotech stock.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 06:05 PM EST PAUL PRICE

    Michael's (MIK) Up on Takeover Rumors

    The NYT says talks are underway regarding a buyout...
  • 08:09 AM EST GARY BERMAN

    Monday Morning Fibocall for 3/1/2021

    Always a good idea to know where our bounce zones ...
  • 11:51 AM EST REAL MONEY

    Watch Bob Lang and Doug Kass Discuss Short-Selling!

    Bob Lang and Doug Kass with an engaging and educat...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login